SCIENTIFIC AGENDA

Session II: Cancer of the pancreas
Chairs: Christophe Louvet, MD and Malcolm J. Moore, MD

Introduction: Evaluation of a pancreatic mass
Christophe Louvet, MD and Malcolm J. Moore, MD

Molecular changes in pancreatic cancer
Margaret A. Tempero, MD

Cystic neoplasms and intraductal tumors of the pancreas
Philippe Ruszniewski, MD

Surgery for pancreatic cancer
Sergio Pedrazolli, MD, FACS

Neoadjuvant and adjuvant treatment of pancreatic cancer
Volker Heinemann, MD, PhD

Selected abstract: Concurrent infusional 5-flurouracil and “PROTOCOL SPECIFIC” 3D conformal radiotherapy is effective and safe in combination with “sandwich” gemcitabine in the management of locally advanced pancreatic cancer
Nigel Spry, et al.

Selected abstract: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201)
Al Benson III et al.

DEBATE 1: The approach to locally advanced pancreatic cancer: How far should diagnostic work-up be done and what is the evidence for the treatment strategies? Short introduction and cases prepared by Christophe Louvet, MD, Malcolm J. Moore, MD

Management of metastatic pancreatic cancer
Malcolm J. Moore, MD